Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …

In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China …

Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally
target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral …

Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously
emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor …

A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …

Background Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed.
The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on …

Summary The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …

In December of 2019, an outbreak of pneumonia caused by an unknown aetiology occurred
in Wuhan, China and most patients were linked to a single seafood market, which reportedly …

Infection is the second leading cause of death in patients with chronic kidney disease (CKD).
Adequate humoral (antibody) and cellular (T cell-driven) immunity are required to minimize …

There have been over seven million cases and almost 413 372 deaths globally due to the
novel coronavirus (2019‐nCoV) associated disease COVID‐19, as of 11 June 2020 …